Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Fig. 1

Ratios to baseline at end-of-treatment for hsCRP with semaglutide and comparators by trial. ‘On-treatment without rescue medication’ data from the full analysis set. Ratios to baseline were analyzed using a mixed model for repeated measurements with treatment as categorical fixed effect and baseline hsCRP value (log-transformed) as covariate, all nested within visit, and an unstructured residual covariance matrix on log-transformed values. CI confidence interval; exenatide ER exenatide extended-release; ETR estimated treatment ratio; hsCRP high-sensitivity C-reactive protein; N number of subjects with available hsCRP data; s.c. subcutaneous

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840